Skip to Main Content

Clinical Studies and Protocols

Site Map Investigators Log-in
(MMA-0610) Randomized Trial of Open-Label Truvada with Atazanavir/ritonavir versus Multi-class Therapy

 Return to List of Clinical Studies
 Return to List of Protocols for HIV and AIDS
A Phase II, Randomized Trial of Open-Label Truvada with Atazanavir/ritonavir versus Multi-class Therapy with Truvada, Atazanavir/ritonavir, Maraviroc and Raltegravir in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (MMA-0610)

Principal Investigator:
Martin H. Markowitz M.D.


Contact Information:
Melissa La Mar
The Rockefeller University
1230 York Avenue
New York, NY 10065
Telephone: 212-327-7280
Enrollment Status:
Closed to Enrollment

Brief Summary of Protocol:
The reason for conducting this research is to see if antiretroviral (ARV) medications that target HIV at 4 different steps in the viral life cycle better prevents HIV from making copies of itself when compared to a standard three-drug treatment commonly used to treat HIV infection that targets 2 different steps in the viral life cycle.

Detailed Description of Protocol:
If you decide to join this study, you will be put in one of two groups.

Group #1

-Will receive a combination of 5 drugs.

Group #2

-Will get standard HIV therapy which consists of 3 drugs.

You have a 2 out of 3 chance of being in the group that receives 5 drugs. Profile:
If you join the research study, you will take part for between 60 and 96 weeks.

The research study as a whole will last about 96 weeks.

About 36 people will take part in the research study.

What specifically makes a person eligible for the study?
You may be eligible to enter this study:

• You have just been diagnosed as having acute (recent) HIV-1 infection.

• You have not taken any ARV medications for more than 7 days at any time prior to study entry.


18 years and older

Children permitted to participate:

Potential Benefits.....
• You may find out during the research study that the medications are helpful to you.

• You may benefit from what we learn in this research study whether the medications help you or not.

• You will receive free monitoring and if randomized to the multiclass arm, you will also receive free medications (raltegravir and maraviroc).

There is no cost to you for being in this research study.

You will not be paid for participation in this research study.